Previous close | 179,700.00 |
Open | 180,200.00 |
Bid | 179,800.00 x 0 |
Ask | 180,000.00 x 0 |
Day's range | 179,100.00 - 180,900.00 |
52-week range | 131,000.00 - 241,000.00 |
Volume | |
Avg. volume | 640,697 |
Market cap | 37.13T |
Beta (5Y monthly) | 0.33 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 06 May 2024 - 10 May 2024 |
Forward dividend & yield | 500.00 (0.28%) |
Ex-dividend date | 27 Dec 2023 |
1y target est | 229,929.00 |
Q4 2023 Rani Therapeutics Holdings Inc Earnings Call
Celltrion USA announced today the availability of a ZYMFENTRA™ (infliximab-dyyb), a subcutaneous (SC) formulation of infliximab.[1] ZYMFENTRA is the first and only subcutaneous infliximab approved by the U.S. Food and Drug Administration (FDA) in 2023.
Celltrion USA today announced that the company has submitted a Biologics License Application (BLA) for CT-P39, an interchangeable biosimilar candidate to XOLAIR® (omalizumab) to the U.S. Food and Drug Administration (FDA).[1]